Diagnosis and Management of Cryptococcal Disease in Resource-Limited Settings
Cryptococcal meningitis is one of the most important fungal infections in the developing world, where deaths related to this disease are numerous. In resource-limited settings, mortality is high in large part because of difficulties in the diagnosis and management of this infection. This paper outlines many of the realities in many resource-limited settings, and describes priorities for public health action and research.
KeywordsCryptococcus Cryptococcosis Cryptococcal meningitis Diagnosis Management HIV/AIDS Resource-limited settings Amphotericin Fluconazole Lateral flow assay Cryptococcal antigen Latex agglutination
The findings and conclusions in this presentation/report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Park BJ, Wannemuehler KA, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. This paper demonstrated the disparity in the burden of cryptococcal disease; it showed that the vast majority of cases were occurring in resource-limited settings. PubMedCrossRefGoogle Scholar
- 27.•• Meya DB, Manabe YC, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448–55. This paper is one of the first to demonstrate the effectiveness of early diagnosis and treatment of cryptococcal disease. PubMedCrossRefGoogle Scholar
- 29.•• Jarvis JN, Percival A, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019–23. This paper demonstrates the utility of a point-of-care test, the lateral flow assay, in the diagnosis of cryptococcal disease. PubMedCrossRefGoogle Scholar
- 30.•• Lindsley MD, Mekha N, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5. This paper demonstrates the utility of a point-of-care test, the lateral flow assay, in the diagnosis of cryptococcal disease. PubMedCrossRefGoogle Scholar